U.S., May 30 -- ClinicalTrials.gov registry received information related to the study (NCT07615426) titled 'A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia' on May 22.
Brief Summary: The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.
Study Start Date: March 02
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: Aticaprant
Participants will receive aticaprant during the double blind (DB) treatment phase.
DRUG: Placebo
Particip...